Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, hosted a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on March 26, 2020.
Tagged with: Capricor Therapeutics
BioFluidica Announces Commercialization of its High Throughput LiquidScan™ Automated Liquid Biopsy System for Capturing Rare Biomarkers on a Single Scalable Platform.
15 hours ago
Vect-Horus and MDimune Collaborate to Develop a Novel Approach to CNS Drug Delivery Based on Vectorized Cell-derived Vesicles (CDVs)
14 days ago
29 days ago